104 related articles for article (PubMed ID: 26721606)
1. Proadifen sensitizes resistant ovarian adenocarcinoma cells to cisplatin.
Jendželovský R; Jendželovská Z; Hiľovská L; Kovaľ J; Mikeš J; Fedoročko P
Toxicol Lett; 2016 Jan; 243():56-66. PubMed ID: 26721606
[TBL] [Abstract][Full Text] [Related]
2. Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells.
Jendželovská Z; Jendželovský R; Hiľovská L; Kovaľ J; Mikeš J; Fedoročko P
Toxicol In Vitro; 2014 Oct; 28(7):1259-73. PubMed ID: 24994473
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells.
Hiľovská L; Jendželovský R; Jendželovská Z; Kovaľ J; Fedoročko P
Int J Oncol; 2015 Oct; 47(4):1572-84. PubMed ID: 26252082
[TBL] [Abstract][Full Text] [Related]
4. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
5. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
[TBL] [Abstract][Full Text] [Related]
6. [Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells].
Zhang MC; Hu CP; Chen Q
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):408-12. PubMed ID: 17152483
[TBL] [Abstract][Full Text] [Related]
7. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway.
Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q
Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
[TBL] [Abstract][Full Text] [Related]
9. Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation.
Ma J; Yang J; Wang C; Zhang N; Dong Y; Wang C; Wang Y; Lin X
Biomed Res Int; 2014; 2014():107671. PubMed ID: 25580427
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
12. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
[TBL] [Abstract][Full Text] [Related]
13. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
14. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
15. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
Sheng WJ; Jiang H; Wu DL; Zheng JH
Braz J Med Biol Res; 2013 Aug; 46(8):650-8. PubMed ID: 23969971
[TBL] [Abstract][Full Text] [Related]
16. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
Jiang L; Luo RY; Yang J; Cheng YX
Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors.
Zhang Z; Liao H; Chen X; Zheng Y; Liu Y; Tao X; Gu C; Dong L; Duan T; Yang Y; Liu X; Yu Y; Feng Y
Eur J Obstet Gynecol Reprod Biol; 2011 Mar; 155(1):69-74. PubMed ID: 21074309
[TBL] [Abstract][Full Text] [Related]
20. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
Wang LJ; Wang SG; Deng TX
Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
